Eso-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders characterized by acid reflux, heartburn, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing symptomatic relief and promoting mucosal healing in conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance by reducing dosing frequency. Eso-D Capsule SR is indicated for patients requiring both acid suppression and prokinetic therapy to manage complex upper gastrointestinal symptoms. It should be used under medical supervision, with caution advised in patients with hepatic impairment, cardiac arrhythmias, or those on medications that may interact with domperidone or esomeprazole. Common adverse effects may include headache, dry mouth, abdominal discomfort, and, rarely, extrapyramidal symptoms. This combination offers a comprehensive approach to managing acid-related gastrointestinal disorders with improved symptom control.